KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Current Assets: 2010-2024

Historic Current Assets for Nektar Therapeutics (NKTR) over the last 15 years, with Dec 2024 value amounting to $261.3 million.

  • Nektar Therapeutics' Current Assets fell 1.79% to $281.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $281.4 million, marking a year-over-year decrease of 1.79%. This contributed to the annual value of $261.3 million for FY2024, which is 20.99% down from last year.
  • Latest data reveals that Nektar Therapeutics reported Current Assets of $261.3 million as of FY2024, which was down 20.99% from $330.7 million recorded in FY2023.
  • Nektar Therapeutics' 5-year Current Assets high stood at $1.1 billion for FY2020, and its period low was $261.3 million during FY2024.
  • For the 3-year period, Nektar Therapeutics' Current Assets averaged around $379.3 million, with its median value being $330.7 million (2023).
  • Data for Nektar Therapeutics' Current Assets shows a maximum YoY plummeted of 39.43% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Nektar Therapeutics' Current Assets stood at $1.1 billion in 2020, then slumped by 30.09% to $795.6 million in 2021, then tumbled by 31.37% to $546.0 million in 2022, then plummeted by 39.43% to $330.7 million in 2023, then fell by 20.99% to $261.3 million in 2024.